1.Advances and challenges in neoadjuvant treatment for colorectal cancer liver metastasis.
Chinese Journal of Gastrointestinal Surgery 2021;24(10):919-924
Liver metastasis is the leading cause of death in patients with colorectal cancer. Since surgical resection alone has a high postoperative recurrence rate, neoadjuvant therapy as an important means is widely applied in order to reduce recurrence and improve survival. Progress has been achieved in many aspects of neoadjuvant therapy in colorectal cancer liver metastasis, such as eligible patients selection, optimal regimens and courses of chemotherapy. However, controversies still remain regarding the standards of resectability of lesions and the application of targeted drugs. Individualized treatments could be developed based on multidisciplinary teamwork to achieve the goal of 'resources integration and treatment stratification'.
Chemotherapy, Adjuvant
;
Colorectal Neoplasms/drug therapy*
;
Humans
;
Liver Neoplasms/drug therapy*
;
Neoadjuvant Therapy
;
Neoplasm Recurrence, Local
3.Expert consensus on intravesical therapy for non-muscle invasive bladder cancer (2021 edition).
Chinese Journal of Oncology 2021;43(10):1027-1033
Bladder cancer is one of the common malignant tumors in China, with 75% of bladder cancer being non-muscle invasion with a high recurrence rate after surgery. Intravesical therapy is an useful methods to either directly kill tumor cells by infusing cytotoxic drugs into the bladder or directly or indirectly induce local immune responses of the body through infusing immune agents, such as bacillus calmette guerin, and thus reduce the risk of tumor recurrence and progression. In 2019, the Urological Chinese Oncology Group issued the "Expert consensus on intravesical therapy on non-muscle invasive bladder cancer" . Recently, great progress in the clinical diagnosis and treatment of non-muscle invasive bladder cancer has been achieved domestically and abroad, including the risk assessment of non-muscle invasive bladder cancer, the therapeutic choice of intravesical drugs, the adverse reactions and treatment experience of intravesical therapy, and clinical research on new types of intravesical drugs. This consensus is made according to domestic and overseas evidence-based medicine in combination with current clinical practice and experience of intravesical therapy for non-muscle invasive bladder cancer in China. It is an update of the 2019 expert consensus, with the wish to provide a guidance for domestic clinical standardized intravesical therapy for non-muscle invasive bladder cancer.
Adjuvants, Immunologic/therapeutic use*
;
Administration, Intravesical
;
Consensus
;
Humans
;
Neoplasm Invasiveness
;
Neoplasm Recurrence, Local/drug therapy*
;
Urinary Bladder Neoplasms/drug therapy*
4.Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).
Jianhua SHI ; Ying CHENG ; Qiming WANG ; Kai LI ; Lin WU ; Baohui HAN ; Gongyan CHEN ; Jianxing HE ; Jie WANG ; Haifeng QIN ; Xiaoling LI
Frontiers of Medicine 2022;16(5):766-772
Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients with short-term relapsed SCLC from ALTER1202. Patients with short-term relapsed SCLC (disease progression within 3 months after completing ⩾ two lines of chemotherapy) in the anlotinib (n = 67) and placebo (n = 34) groups were analyzed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival, objective response rate (ORR), disease control rate, and safety. Anlotinib significantly improved median PFS/OS (4.0 vs. 0.7 months, P < 0.0001)/(7.3 vs. 4.4 months, P = 0.006) compared with placebo. The ORR was 4.5%/2.9% in the anlotinib/placebo group (P = 1.000). The DCR in the anlotinib group was higher than that in the placebo group (73.1% vs. 11.8%, P < 0.001). The most common adverse events (AEs) were hypertension (38.8%), loss of appetite (28.4%), and fatigue (22.4%) in the anlotinib group and gammaglutamyl transpeptidase elevation (20.6%) in the placebo group. No grade 5 AEs occurred. For patients with short-term relapsed SCLC, third- or further-line anlotinib treatment was associated with improved survival benefit. Further studies are warranted in this regard.
Humans
;
Lung Neoplasms/drug therapy*
;
Treatment Outcome
;
Neoplasm Recurrence, Local/chemically induced*
;
Quinolines/adverse effects*
5.Clinical Characteristics of Multiple Myeloma Patients with Early Relapse.
Ting CHEN ; Jia-Mei JI ; Ya-Ting LI ; Lei FAN ; Li-Juan CHEN ; Jian-Yong LI ; Xiao-Yan QU
Journal of Experimental Hematology 2022;30(4):1144-1149
OBJECTIVE:
To analyze the clinical characteristics of multiple myeloma(MM) patients with early relapse.
METHODS:
A total of 50 MM patients with early relapse (≤12 months) and 50 matched controls with late relapse (>12 months) were selected. The time from diagnosis to relapse and related clinical data of the 100 patients were retrospectively analyzed, and the factors associated with early relapse were identified. Kaplan-Meier curve was used to analyze the overall survival (OS) time of the whole cohort. Area under the curve (AUC) was used to evaluate the effect of circulating plasma cells on early recurrence of the patients.
RESULTS:
The results showed that high-risk cytogenetics (FISH) (P=0.005), and ISS stage III (P=0.008) were associated with early recurrence of the patients. For patients with early relapse, high-risk FISH showed poor survival. Compared with the patients with late relapse, most of the chromosome karyotype of patients with early relapse showed quantitative and structural abnormalities. The expression of circulating plasma cells was significantly increased in patients with early recurrence group (P=0.0318). The response to initial treatment was poor in the early recurrence group (P=0.001), and the prognosis was significantly worse than those in the late recurrence group (median OS: 38 vs 81 months, P=0.002).
CONCLUSION
Early relapse is a marker poor prognostic in MM patients, and such patients should be focused on the improving their prognosis.
Cytogenetics
;
Humans
;
Multiple Myeloma/drug therapy*
;
Neoplasm Recurrence, Local
;
Prognosis
;
Retrospective Studies
6.Surgical Management of Recurrent Cervical Cancer.
Alberto E SELMAN ; Larry J COPELAND
Yonsei Medical Journal 2002;43(6):754-762
The majority of patients with recurrent cervical cancer are incurable and treatment is based on the type of primary therapy delivered. Only a very small percentage of the patients with recurrent cervical cancer following primary radiotherapy will have central pelvic recurrences that are amenable to surgical resection and curable by pelvic exenteration. These procedures should be undertaken only after the completion of exhaustive attempts to exclude extrapelvic disease.
Cervix Neoplasms/drug therapy/mortality/*surgery
;
Female
;
Human
;
Neoplasm Recurrence, Local/drug therapy/mortality/*surgery
;
Pelvic Exenteration/adverse effects/methods
9.Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
Hyejeong HUE ; Kidong KIM ; HyoJin KIM ; Dong Hoon SUH ; Jae Hong NO ; Yong Beom KIM
Obstetrics & Gynecology Science 2019;62(4):285-289
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
Carboplatin
;
Cisplatin
;
Drug Therapy
;
Humans
;
Infusions, Parenteral
;
Neoplasm Recurrence, Local
;
Ovarian Neoplasms
;
Paclitaxel
;
Peritoneal Cavity
;
Peritoneal Neoplasms
;
Recurrence
;
Topotecan
10.No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery
Tae In YOON ; Jong Won LEE ; Sae Byul LEE ; Guiyun SOHN ; Jisun KIM ; Il Young CHUNG ; Hee Jeong KIM ; Beom Seok KO ; Byung Ho SON ; Gyungyub GONG ; Sung Bae KIM ; Su Ssan KIM ; Seung Do AHN ; Minsung CHUNG ; Sei Hyun AHN
Cancer Research and Treatment 2018;50(1):275-282
PURPOSE: We evaluated the effect of positive superficial and/or deep margin status on local recurrence (LR) in invasive breast cancer treated with breast-conserving surgery (BCS) followed by radiotherapy. MATERIALS AND METHODS: In total, 3,403 stage 1 and 2 invasive breast cancer patients treated with BCS followed by radiotherapy from January 2000 to December 2008 were included in this study. These patients were divided into three groups according to margin status: clear resection margin status for all sections (group 1, n=3,195); positive margin status in superficial and/or deep sections (group 2, n=121); and positive peripheral parenchymal margin regardless of superficial and/or deep margin involvement (group 3, n=87). The LR-free survival between these three groups was compared and the prognostic role of margin status was analyzed. RESULTS: Across all groups, age, tumor size, nodal status, and human epidermal growth factor receptor 2 status did not significantly differ. High grade, positive extensive intraductal component, hormone receptor positivity, hormone therapy received, and chemotherapy not received were more prevalent in groups 2 and 3 than in group 1. Five-year LR rates in groups 1, 2, and 3 were 1.9%, 1.7%, and 7.7%, respectively. Multivariate analysis revealed that group 3 was a significant predictor for LR (hazard ratio [HR], 4.78; p < 0.001), but that positive superficial and/or deep margin was not (HR, 0.66; p=0.57). CONCLUSION: Superficial and/or deep margin involvement following BCS is not an important predictor for LR.
Breast Neoplasms
;
Breast
;
Drug Therapy
;
Humans
;
Mastectomy, Segmental
;
Multivariate Analysis
;
Neoplasm Recurrence, Local
;
Radiotherapy
;
Receptor, Epidermal Growth Factor
;
Recurrence